Genentech Manufacturing Expansion in Holly Springs

planned

Roche and Genentech are investing $700 million in a state-of-the-art manufacturing facility in Holly Springs, North Carolina. The 700,000 square feet facility on a 100-acre site will integrate advanced automation, digital tools, and sustainable production systems to scale high-precision metabolic therapies, particularly targeting obesity treatments. The project is part of a broader $50 billion U.S. biotech expansion and aims to create over 400 high-wage manufacturing jobs and 1,500 construction jobs. The facility is expected to be operational by 2029 and includes future expansion space to adapt to biotech innovation demands.